Synthesis, crystal structure and anticancer activity of tetrakis(N-isopropylimidazolidine-2-selenone)platinum(II) chloride

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15310%2F18%3A73591071" target="_blank" >RIV/61989592:15310/18:73591071 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/pii/S0022286017312565" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0022286017312565</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.molstruc.2017.09.068" target="_blank" >10.1016/j.molstruc.2017.09.068</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Synthesis, crystal structure and anticancer activity of tetrakis(N-isopropylimidazolidine-2-selenone)platinum(II) chloride

Popis výsledku v původním jazyce

A Platinum(II) complex of N-isopropylimidazolidine-2-selenone (i-PrImSe), [Pt(i-PrImSe)(4)]Cl-2 (1) was prepared and characterized by elemental analysis, IR and NMR H-1, C-13, Se-77 &amp; Pt-195) spectroscopy, and X-ray crystallography. The structure of 1 consists of [Pt(i-PrImSe)(4)](2+)complex ion and chloride counter ions. The platinum(II) atom adopts a distorted square planar geometry. The in vitro antitumor activity of 1 as well as cisplatin, was evaluated by MTT assay against human; ovarian carcinoma A2780 and its cisplatin-resistant subline A2780R, prostate cancer 22Rv1 and breast cancer MCF-7 cell lines. The title complex displayed the activity against the A2780 cells (IC50 = 30.8 mu M) at the level comparable to cisplatin (IC50 = 26.8 mu M). The interaction studies with sulfur-containing biomolecules revealed its ability to form a variety of intermediates and oxidized species with L-cysteine and reduced glutathione. (c) 2017 Elsevier B.V. All rights reserved.

Název v anglickém jazyce

Synthesis, crystal structure and anticancer activity of tetrakis(N-isopropylimidazolidine-2-selenone)platinum(II) chloride

Popis výsledku anglicky

A Platinum(II) complex of N-isopropylimidazolidine-2-selenone (i-PrImSe), [Pt(i-PrImSe)(4)]Cl-2 (1) was prepared and characterized by elemental analysis, IR and NMR H-1, C-13, Se-77 &amp; Pt-195) spectroscopy, and X-ray crystallography. The structure of 1 consists of [Pt(i-PrImSe)(4)](2+)complex ion and chloride counter ions. The platinum(II) atom adopts a distorted square planar geometry. The in vitro antitumor activity of 1 as well as cisplatin, was evaluated by MTT assay against human; ovarian carcinoma A2780 and its cisplatin-resistant subline A2780R, prostate cancer 22Rv1 and breast cancer MCF-7 cell lines. The title complex displayed the activity against the A2780 cells (IC50 = 30.8 mu M) at the level comparable to cisplatin (IC50 = 26.8 mu M). The interaction studies with sulfur-containing biomolecules revealed its ability to form a variety of intermediates and oxidized species with L-cysteine and reduced glutathione. (c) 2017 Elsevier B.V. All rights reserved.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10402 - Inorganic and nuclear chemistry

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

JOURNAL OF MOLECULAR STRUCTURE

ISSN

0022-2860

e-ISSN

—

Svazek periodika

1152

Číslo periodika v rámci svazku

JAN

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

5

Strana od-do

232-236

Kód UT WoS článku

000415774400025

EID výsledku v databázi Scopus

2-s2.0-85030166546